437 related articles for article (PubMed ID: 23543450)
41. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
Marcus R; Wong M; Heath H; Stock JL
Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
[TBL] [Abstract][Full Text] [Related]
42. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
[TBL] [Abstract][Full Text] [Related]
43. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
44. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
J Endocrinol Invest; 2014 Aug; 37(8):769-773. PubMed ID: 25008458
[TBL] [Abstract][Full Text] [Related]
45. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
46. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
47. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
[TBL] [Abstract][Full Text] [Related]
48. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.
Ellis AG; Reginster JY; Luo X; Cappelleri JC; Chines A; Sutradhar S; Jansen JP
Value Health; 2014 Jun; 17(4):424-32. PubMed ID: 24969003
[TBL] [Abstract][Full Text] [Related]
49. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
51. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.
Freemantle N; Cooper C; Diez-Perez A; Gitlin M; Radcliffe H; Shepherd S; Roux C
Osteoporos Int; 2013 Jan; 24(1):209-17. PubMed ID: 22832638
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
54. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
55. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Ellis AG; Reginster JY; Luo X; Bushmakin AG; Williams R; Sutradhar S; Mirkin S; Jansen JP
Curr Med Res Opin; 2014 Aug; 30(8):1617-26. PubMed ID: 24773456
[TBL] [Abstract][Full Text] [Related]
56. Treatment of primary osteoporosis in men.
Giusti A; Bianchi G
Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
[TBL] [Abstract][Full Text] [Related]
57. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
58. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
59. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
Ouyang Y; Chen S; Wan T; Zheng G; Sun G
Medicine (Baltimore); 2021 Feb; 100(7):e24839. PubMed ID: 33607854
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]